Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Post-transplant Lymphoproliferative Disease”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00005802
What this trial is testing

Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia

Who this might be right for
Leukemia
Fred Hutchinson Cancer Center
Testing effectiveness (Phase 2)WithdrawnNCT03241017
What this trial is testing

Durvalumab in DLBCL After Autologous Transplant

Who this might be right for
Lymphoma, Large B-Cell, Diffuse
Insel Gruppe AG, University Hospital Bern
Early research (Phase 1)Ended earlyNCT00469820
What this trial is testing

Vaccine Therapy With or Without Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Multiple Myeloma Undergoing Donor Stem Cell Transplant

Who this might be right for
LeukemiaMultiple Myeloma and Plasma Cell Neoplasm
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 1
Large-scale testing (Phase 3)Ended earlyNCT00324324
What this trial is testing

Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant

Who this might be right for
Breast CancerChronic Myeloproliferative DisordersGestational Trophoblastic Tumor+9 more
OHSU Knight Cancer Institute 240
Post-approval studies (Phase 4)Looking for participantsNCT07029958
What this trial is testing

Improved Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Protocol for the Treatment of Epstein Barr Virus T/NK Lymphoproliferative Disease (EBV-T/NK LPD) and Prevention of Post Transplant Graft-versus-host Disease

Who this might be right for
EBV-T/NK LPD
Beijing Children's Hospital 48
Testing effectiveness (Phase 2)Study completedNCT01323920
What this trial is testing

Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors

Who this might be right for
LeukemiaLymphomaMyelodysplastic Syndrome
Dana-Farber Cancer Institute 35
Early research (Phase 1)Study completedNCT02431208
What this trial is testing

Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

Who this might be right for
Multiple Myeloma
Hoffmann-La Roche 85
Testing effectiveness (Phase 2)UnknownNCT04378647
What this trial is testing

BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant

Who this might be right for
Hodgkin Lymphoma, Adult
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea 150
Testing effectiveness (Phase 2)Active Not RecruitingNCT02861417
What this trial is testing

Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

Who this might be right for
Hematopoietic and Lymphoid Cell NeoplasmHigh Risk Acute Myeloid LeukemiaHigh Risk Myelodysplastic Syndrome+11 more
M.D. Anderson Cancer Center 204
Testing effectiveness (Phase 2)Study completedNCT01009840
What this trial is testing

IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients

Who this might be right for
Multiple Myeloma
Otsuka Pharmaceutical Development & Commercialization, Inc. 30
Early research (Phase 1)Ended earlyNCT00036855
What this trial is testing

Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma

Who this might be right for
AIDS-related Peripheral/Systemic LymphomaAIDS-related Primary CNS LymphomaPost-transplant Lymphoproliferative Disorder+4 more
National Cancer Institute (NCI) 36
Early research (Phase 1)Study completedNCT00255710
What this trial is testing

Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer

Who this might be right for
Chronic Myeloproliferative DisordersGraft Versus Host DiseaseLeukemia+4 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 60
Early research (Phase 1)Ended earlyNCT01954784
What this trial is testing

Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma

Who this might be right for
Refractory Multiple MyelomaStage I Multiple MyelomaStage II Multiple Myeloma+1 more
Case Comprehensive Cancer Center 8
Testing effectiveness (Phase 2)Study completedNCT00003116
What this trial is testing

High-Dose Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Who this might be right for
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+2 more
Case Comprehensive Cancer Center 66
Testing effectiveness (Phase 2)Study completedNCT03389035
What this trial is testing

Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT

Who this might be right for
Acute Lymphoblastic Leukemia, in Relapse
Fondazione Matilde Tettamanti Menotti De Marchi Onlus 21
Not applicableLooking for participantsNCT06463717
What this trial is testing

Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not

Who this might be right for
Multiple MyelomaMinimal Residual Disease
First Affiliated Hospital of Zhejiang University 210
Testing effectiveness (Phase 2)Study completedNCT01789255
What this trial is testing

Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities+115 more
National Cancer Institute (NCI) 12
Testing effectiveness (Phase 2)Ended earlyNCT02700841
What this trial is testing

Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation

Who this might be right for
Plasma Cell Myeloma
University of Nebraska 8
Testing effectiveness (Phase 2)Study completedNCT01010217
What this trial is testing

Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide

Who this might be right for
Blood Stem Cell Transplant FailureLeukemiaHematologic Malignancies
M.D. Anderson Cancer Center 176
Testing effectiveness (Phase 2)Study completedNCT00742027
What this trial is testing

Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma

Who this might be right for
Classical Hodgkin's Lymphoma
Novartis Pharmaceuticals 129
Next Page